Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer

This is a Phase 2b, multicenter, open-label study to evaluate the safety and efficacy of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC (Non-resistant Uncommon EGFR Mutations Only, Including L861Q, G719X, and/or S768I)

Trial Details

NCT ID
NCT05168566
Phase
PHASE2
Sponsor
Teligene US
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • Sutetinib Maleate Capsule
Locations (sample)
  • Glendale, California, United States|34.14251,-118.25508
  • Athens, Georgia, United States|33.96095,-83.37794
  • Louisville, Kentucky, United States|38.25424,-85.75941
  • Baltimore, Maryland, United States|39.29038,-76.61219
  • Pinehurst, North Carolina, United States|35.19543,-79.46948

Key Eligibility Criteria

  • Age 18 years old and above, male or female.
  • Histopathological and/or cytopathological confirmation of locally advanced or metastatic NSCLC patients with ≤ 1 prior line of chemotherapy.
  • Confirmation that the tumor harbors a non-resistant uncommon EGFR mutation (tumor tissue biopsy), including one or more of L861Q, G719X and S768I m…
  • At least one measurable lesion.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →